Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice

  1. Shun Kishimoto
  2. Jeffrey R Brender  Is a corresponding author
  3. Daniel R Crooks
  4. Shingo Matsumoto
  5. Tomohiro Seki
  6. Nobu Oshima
  7. Hellmut Merkle
  8. Penghui Lin
  9. Galen Reed
  10. Albert P Chen
  11. Jan Henrik Ardenkjaer-Larsen
  12. Jeeva Munasinghe
  13. Keita Saito
  14. Kazutoshi Yamamoto
  15. Peter L Choyke
  16. James Mitchell
  17. Andrew N Lane
  18. Teresa Fan
  19. W Marston Linehan
  20. Murali C Krishna  Is a corresponding author
  1. National Cancer Institute, National Institutes of Health, United States
  2. Hokkaido University, Japan
  3. National Institute of Neurological Disorders and Stroke, National Institutes of Health, United States
  4. University of Kentucky, United States
  5. GE Healthcare, Canada

Abstract

Metabolic differences among and within tumors can be an important determinant in cancer treatment outcome. However, methods for determining these differences non-invasively in vivo is lacking. Using pancreatic ductal adenocarcinoma as a model, we demonstrate that tumor xenografts with a similar genetic background can be distinguished by their differing rates of the metabolism of 13C labeled glucose tracers, which can be imaged without hyperpolarization using newly developed techniques for noise suppression. Using this method, cancer subtypes that appeared to have similar metabolic profiles based on steady state metabolic measurement can be distinguished from each other. The metabolic maps from 13C-glucose imaging localized lactate production and overall glucose metabolism to different regions of some tumors. Such tumor heterogeneity was not detectable in FDG-PET.

Data availability

Glucose imaging data and related files have been deposited to Dataverse at https://doi.org/10.7910/DVN/XU9XH9

Article and author information

Author details

  1. Shun Kishimoto

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  2. Jeffrey R Brender

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    For correspondence
    cherukum@mail.nih.gov
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7487-6169
  3. Daniel R Crooks

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  4. Shingo Matsumoto

    Graduate School of Information Science and Technology, Division of Bioengineering and Bioinformatics, Hokkaido University, Sapporo, Japan
    Competing interests
    No competing interests declared.
  5. Tomohiro Seki

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  6. Nobu Oshima

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  7. Hellmut Merkle

    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  8. Penghui Lin

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  9. Galen Reed

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Galen Reed, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  10. Albert P Chen

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Albert P Chen, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  11. Jan Henrik Ardenkjaer-Larsen

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Jan Henrik Ardenkjaer-Larsen, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  12. Jeeva Munasinghe

    In Vivo NMR Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  13. Keita Saito

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  14. Kazutoshi Yamamoto

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  15. Peter L Choyke

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  16. James Mitchell

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  17. Andrew N Lane

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  18. Teresa Fan

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  19. W Marston Linehan

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  20. Murali C Krishna

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    For correspondence
    murali@helix.nih.gov
    Competing interests
    No competing interests declared.

Funding

National Cancer Institute (1ZIASC006321-39)

  • James Mitchell

National Cancer Institute (Intramural Research Program)

  • Murali C Krishna

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The animal experiments were conducted according to a protocol approved by the Animal Research Advisory Committee of the NIH (RBB-159-2SA) in accordance with the National Institutes of Health Guidelines for Animal Research.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 3,494
    views
  • 425
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shun Kishimoto
  2. Jeffrey R Brender
  3. Daniel R Crooks
  4. Shingo Matsumoto
  5. Tomohiro Seki
  6. Nobu Oshima
  7. Hellmut Merkle
  8. Penghui Lin
  9. Galen Reed
  10. Albert P Chen
  11. Jan Henrik Ardenkjaer-Larsen
  12. Jeeva Munasinghe
  13. Keita Saito
  14. Kazutoshi Yamamoto
  15. Peter L Choyke
  16. James Mitchell
  17. Andrew N Lane
  18. Teresa Fan
  19. W Marston Linehan
  20. Murali C Krishna
(2019)
Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice
eLife 8:e46312.
https://doi.org/10.7554/eLife.46312

Share this article

https://doi.org/10.7554/eLife.46312

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Simei Go, Constantinos Demetriou ... Eric O Neill
    Research Article

    The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.

    1. Cancer Biology
    Hyungtai Sim, Hyun Jung Park ... Murim Choi
    Research Article

    Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.